IP Library Granted Patent US 10,744,236
Granted Patent B2
US 10,744,236 · App. 15/987,827 · Granted Aug 18, 2020

Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof

Inventor: David B. Masters (Minneapolis, MN)
Assignee: PETVIVO HOLDINGS, INC.
A61L31/16A61L24/0015A61L24/043A61L24/108A61L27/26A61L27/507A61L27/54A61L31/041A61L31/047A61L2300/802
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,744,236
App. No.
15/987,827
Granted
Aug 18, 2020
Kind
B2
Abstract

The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.

Claims (12)

1. A vessel graft system comprising: one or more tube(s), the tubes including a first biomaterial formed from one or more precipitated amorphous thermoplastic biocoacervate(s) having a plurality of aggregated complexes, the aggregated complexes having homogenously distributed components including one or more soluble or solubilized primary proteins combined with one or more glycosaminoglycans and one or more biocompatible solvents, the biocoacervate(s) are formed into a tubular configuration and crosslinked with one or more crosslinking agents;

and one or more biological fastener(s) positioned at one or more end(s) of one or more of the tube(s), the fasteners comprising a second biomaterial formed from the one or more precipitated amorphous thermoplastic biocoacervate(s) that are crosslinked with the one or more crosslinking agents.

2. The vessel graft system of claim 1 wherein the biological fasteners are selected from the group consisting of sutures, threads, wraps, staples, bioglues and adhesives.

3. The vessel graft system of claim 1 wherein the biocoacervates of the tube(s) and/or biological fastener(s) are the same material.

4. The vessel graft system of claim 1 wherein the tube includes a structural scaffolding coated or encapsulated with the thermoplastic biocoacervate(s).

5. The vessel graft system of claim 1 wherein the one or more primary proteins are selected from the group consisting of collagen, laminin, bone morphogenic protein and its isoforms that contain glycosaminoglycan binding sites, albumin, interleukins, epidermal growth factors, fibronectin, thrombin, aprotinin and antithrombin III.

6. The vessel graft system of claim 1 wherein the one or more glycosaminoglycans are selected from the group consisting of heparin, heparin sulfate, keratan sulfate, dermatin, dermatin sulfate, heparin-hyaluronic acid, chondroitin, chondroitin sulfate, chondroitin 6-sulfate, chondroitin 4-sulfate, chitin, chitosan, acetyl-glucosamine, hyaluronic acid, aggrecan, decorin, biglycan, fibromodulin, lumican and complexes thereof.

7. The vessel graft system of claim 1 wherein the tube(s), biological fastener(s) or both tube(s) and fastener(s) further include one or more secondary proteins selected from the group consisting of fibrin, fibrinogen, elastin, albumin, ovalbumin, keratin, silk, silk fibroin, actin, myosin, thrombin, aprotinin and antithrombin III.

8. The vessel graft system of claim 1 wherein the one or more biocompatible solvents are selected from the group consisting of water, dimethyl sulfoxide (DMSO), biocompatible alcohols, biocompatible acids, oils and biocompatible glycols.

9. The vessel graft system of claim 1 further comprising one or more pharmacologically active agents selected from the group consisting of analgesics, anesthetics, antiproliferative agents, angiogenesis inhibitors, angiogenic growth factors, steroids, antisteroids, corticosteroids, antiglacoma agents, antialcohol agents, anti-coagulant agents, genetic material, antithrombolytic agents, anticancer agents, anti-inflammatory agents, anticonception agents, enzymes agents, cells, growth factors, antiviral agents, antibacterial agents, antifungal agents and chemoattractants.

10. The vessel graft system of claim 1 wherein the one or more crosslinking agents are selected from the group consisting of glutaraldehyde, 1,4-butandiol diglycidylether, formaldehyde, glyoxal, sebacic acid bis(N-succinimidyl) ester (DSS), p-Azidobenzolyl Hydazide, N-5-Azido 2-nitrobenzoyloxysuccinimide, N-Succinimidyl 6-[4′ azido-2′ nitro-phenylamino]hexanoate and 4-[p-Azidosalicylamido] butylamine.

11. The vessel graft system of claim 1 wherein the biomaterial included in the tube(s), fastener(s) or both tube(s) and fastener(s) include collagen, heparin, elastin and water.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2020
From: MASTERS, DAVID B.
To: GEL-DEL TECHNOLOGIES, INC
Reel/Frame 054286/0581 →
MERGER Recorded May 31, 2019
From: GEL-DEL TECHNOLOGIES, INC.
To: PETVIVO HOLDINGS, INC.
Reel/Frame 049336/0741 →
Continuity (3)
Continuation 13131083
Provisional Application 61115375 · Nov 17, 2008
Related Publication 20190117855A1 · Apr 25, 2019